Please assess the completion status of the following clinical trial:

Trial Title: Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to provide written, informed consent.~2. A clinical diagnosis of hereditary angioedema Type 1 or Type 2 as documented at any time in the medical records or at the screening visit.~3. Access to and ability to use standard of care acute attack treatment for attacks of HAE.~4. Sexually active women of child-bearing potential and sexually active men must utilize effective contraception.~Exclusion Criteria:~1. Women who are pregnant or breast-feeding.~2. Any clinical condition or medical history that would interfere with the subject's safety or ability to participate in the study.~3. Use of C1INH, androgens or tranexamic acid for prophylaxis of HAE attacks.~4. History of or current alcohol or drug abuse.~5. Infection with hepatitis B, hepatitis C or HIV.~6. Participation in any other investigational drug study currently or within the last 30 days.~7. Positive drugs of abuse screen (unless as used as medical treatment, e.g., with a prescription).~8. An immediate family relationship to either Sponsor employees, the Investigator or employees of the study site.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Part1: BCX7353 750 mg (Type: EXPERIMENTAL): None
- Part 2: BCX7353 500 mg (Type: EXPERIMENTAL): None
- Part 3: BCX7353 250 mg (Type: EXPERIMENTAL): None
- Parts 1, 2 and 3: placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).